XVIVO Perfusion AB
GOTHENBURG, SE / ACCESSWIRE / October 21, 2021 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)
Third quarter 2021 (Jul 1 - Sep 30)
• Net sales amounted to SEK 54.9 million (42.7), corresponding to an increase of 29 percent in SEK and 31 percent in local currencies.
• Net sales of non-durable goods amounted to SEK 48.9 million (42.3), corresponding to an increase of 16 percent in SEK and 18 percent in local currencies.
• Sales growth for the quarter consisted entirely of revenue from the Abdominal business area, which was not included in the comparison quarter. For Thoracic, sales for the quarter were in line with the previous year's quarter.
• Machine perfusion accounted for 53 percent (41) of net sales.
• Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 5.3 million (9.3), corresponding to an adjusted EBITDA margin of 10 percent (22). Reported EBITDA amounted to SEK 4.2 million (-11.2), corresponding to an EBITDA margin of 8 percent (-26).
• Adjusted operating profit (EBIT) amounted to SEK -2.9 million (1.8). Reported EBIT amounted to SEK -4.0 million (-18.7).
• Net profit amounted to SEK -1.1 million (-14.7). Earnings per share amounted to SEK -0.04 (-0.51).
• Cash and cash equivalents at the end of the quarter amounted to SEK 284.5 million (608.4).
Significant events during the quarter
• Strategic focus areas were presented at XVIVO's first Capital Markets Day. These will support the company's goal to become the leading player in the transplant industry during the strategy period 2022-2026.
• XVIVO participated with a strong presence at the ESOT Congress in Milan. The focus of the congress on machine perfusion was very evident.
• A pilot project in advanced data analysis from liver perfusion was initiated with UMC Groningen as a partner.
The period 2021 (Jan 1 - Sep 30)
• Net sales amounted to SEK 172.5 million (119.6), corresponding to an increase of 44 percent in SEK and 54 percent in local currencies. Net sales of non-durable goods amounted to SEK 160.0 million (114.5), corresponding to an increase of 40 percent in SEK and 50 percent in local currencies.
• Machine perfusion accounted for 52 percent (36) of net sales.
• Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 20.0 million (13.4), corresponding to an adjusted EBITDA margin of 12 percent (11). Reported EBITDA amounted to SEK 13.9 million (-9.1), corresponding to an EBITDA margin of 8 percent (-8).
• Adjusted operating profit (EBIT) amounted to SEK -4.1 million (-8.8). Reported EBIT amounted to SEK -10.2 million (-31.3).
• Net profit amounted to SEK -4.0 million (-24.2). Earnings per share amounted to SEK -0.14 (-0.91).
• Cash and cash equivalents at the end of the period amounted to SEK 284.5 million (608.4).
Significant events in the period
• Publication in reputable scientific journal The New England Journal of Medicine shows significant benefits of oxygenated cold machine perfusion prior to liver transplantation.
• The 510(k) application for Kidney Assist Transport was submitted to the FDA.
• Guidelines from NICE supporting EVLP as the standard lung preservation procedure were issued in the UK.
CEO comment
"XVIVO had an eventful and intensive third quarter. In August, the company launched a new strategy for the coming five years to support our goal of becoming the global leader in the transplantation industry for all major organs. Abdominal made its strongest sales quarter for the year while Thoracic showed a decline, attributable to a temporarily reduced number of lung transplants in the US. We expect a gradual increase in the number of transplants in all markets as the number of new Covid-19 cases decreases and in our main market, the US, September and October have shown positive trends."
Conference call
CEO Dag Andersson och CFO Kristoffer Nordström will present the report in a conference call today at 2 PM CET. Telephone UK: +44 333 300 0804, USA: +1 631 913 1422 or Sweden: +46 8 566 426 51 PIN: 13466713#
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-10-21 07:30 CEST.
SOURCE: XVIVO Perfusion AB
View source version on accesswire.com:
https://www.accesswire.com/669059/XVIVO-Presents-Interim-Report-January-September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Conga Hosts Premier European Customer Conference "Conga Connection EMEA 2025" in Paris18.9.2025 10:00:00 CEST | Press release
Leading B2B SaaS Company to Host More Than 150 Customers and Partners at Flagship EMEA Event October 8 LONDON, UK / ACCESS Newswire / September 18, 2025 / Conga, the market leader in AI-powered innovation in configure, price, quote (CPQ) and contract lifecycle management (CLM), and Document Automation, will host its flagship European customer conference, Conga Connection EMEA 2025, taking place October 8, at the prestigious Pullman Paris Tour Eiffel. The event is expected to attract more than 150 customers, partners, and industry leaders from across Europe for a day of learning, innovation, and networking focused on advancing business transformation and operational excellence. The conference will feature keynote presentations from Conga's executive leadership, including CEO Dave Osborne who will share Conga's strategic vision for empowering organizations to accelerate their journey to become a more connected, intelligent business, better able to minimize risk and maximize revenue. Cong
Karbon-X Corp. Files Year-End Financial Results17.9.2025 14:00:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / September 17, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Form 10-K with audited financial results for the fiscal year ended May 31, 2025. The full filing is available under the Company's profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview Operational and Strategic Highlights for Fiscal Year 2025 Completed the acquisition of ALLCOT Group, expanding Karbon-X's global footprint and integrating world-class expertise. Launched trading operations, marking a critical milestone in validating the Company's business model and initiating its revenue-generating activities. Entered landmark partnerships with major energy producers and with the BK Dukes, reflecting strong market confidence in Karbon-X's vision and capabilities. Financial Highlights for Fiscal Year 2025 Revenue surged to $3.16 million, up from $0.41 million in the prior year, mark
TruMerit Adds Two More Global Credentials for Rehabilitation Care Workers16.9.2025 20:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 16, 2025 / TruMerit, a global leader in healthcare workforce development, today launched two new global credentials for healthcare workers specializing in rehabilitation, habilitation, and restorative care. The Certified Global Health Worker-Rehabilitation (CGHW-R) and the Certified Global Health Worker-Rehabilitation Advanced (CGHW-RA) have been developed specifically for eligible health workers worldwide who wish to have their applied experience and competencies in rehab care recognized and verified by passing a certification examination. These credentials, along with the Certified Global Nurse-Rehabilitation (CGN-R) that TruMerit established last year, are intended to advance and improve services for the more than two billion people worldwide who need this care. The CGHW-RA credential was developed for those with a degree or diploma in a rehabilitation field. These include clinicians, educators, and instructors with physiotherapy, occup
Second Blue Magic Netherlands Event Set for November 1816.9.2025 18:30:00 CEST | Press release
Registration Site Is Open and Dutch Innovators Are Encouraged to Attend and Apply to Present Capabilities SAN DIEGO, CALIFORNIA / ACCESS Newswire / September 16, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI), in collaboration with the Dutch Ministry of Defence and the Dutch Ministry of Economic Affairs, will host its second Blue Magic Netherlands (BMNL) event on November 18, 2025. BMNL 2025 follows the successful first event in 2024 and will take place at the MELT at Avular building, a world-class venue for technology interchange near Brainport Eindhoven, the center of the Dutch high-technology manufacturing industry. The registration site can be accessed at www.ga-asi.com/blue-magic-netherlands-2025. "The first BMNL event was a huge success for Dutch industry," said Brad Lunn, managing director for GA-ASI. "We've built strong investment opportunities with Dutch companies - including Arceon, Emergent Swarm Solutions, and Saluqi Motors - and now we're looking to build on th
U.S. Polo Assn. Celebrates Sport and Style as Official Apparel Sponsor of the 2025 Engel & Völkers Berlin Maifeld Polo Cup16.9.2025 13:00:00 CEST | Press release
Sports Brand Supports Germany's High-Goal Polo Event for Sixth Consecutive Year BERLIN, GERMANY AND WEST PALM BEACH, FL / ACCESS Newswire / September 16, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly partnered as the Official Jersey and Apparel Sponsor of the Engel & Völkers Berlin Maifeld Polo Cup, also known as the German High-Goal Championship 2025, held August 22-31, 2025, in Berlin. This prestigious tournament is the pinnacle of the polo season in Germany and is one of the most celebrated events in European polo.Engel & Völkers Berlin Maifeld Polo Cup Winners Photo Credit: Guadalupe Aizaga The finals weekend for the Engel & Völkers Berlin Maifeld Polo Cup took place at the iconic Maifeld Stadium, the same historic venue where the sport of polo was last played in the 1936 Olympic Games. Qualifying matches were held August 21-28 at the Prussian Polo and Country Club, leading to a thrilling finale that showcased the very best
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom